You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SLB reports strong Q4 earnings, but with clients becoming cautious in their discretionary spending, demand for its products & services is likely to be hurt.
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
Here, we present some insights into GCT's recent performance, market trends, and potential trajectory and discuss whether the stock is worth investing in.
C's business-restructuring efforts, along with the Fed rate cuts, look encouraging. Let us delve into other factors to analyze how to approach the C stock.
KNX's fourth-quarter 2024 performance is expected to have been weighed down by high costs related to driver wages, equipment, maintenance, fuel, and other expenses.
ERIC is expected to record a top-line expansion year over year in the fourth quarter of 2024, driven by healthy demand across several sectors and portfolio strength.
The decreases in Energy Fuels' stock price and uranium prices have left investors confused about whether to buy the dip or wait for better clarity. Let us analyze.
GAP's brand strength, digital innovation and growth initiatives make it a top pick in retail. Strong fundamentals and undervaluation offer great investment potential.
POWL's strong prospects, driven by strength across its end markets, robust bookings, diversification efforts and attractive valuation, make it an ideal pick for investors.
PEP completes the buyout of Siete for $1.2 billion. This acquisition looks to expand its food portfolio, including nutritious, simple foods and ingredients.
KNSL is set to gain from focus on the excess and supply market, prudent underwriting, lower expense ratio, solid investment portfolio and capital deployment.
The Zacks Outsourcing industry is well-positioned to gain from rising demand for business process outsourcing and AI and ML. PAYX, G, and BBSI are three stocks that are prime candidates to ride the demand wave.
The banks and other Finance companies gave us a strong start to the Q4 earnings season. However, we will see if this favorable trend continues as the Q4 reporting cycle really ramps up in the coming days.
Zacks.com Most Recent Articles
Should Investors Steer Clear of SLB Stock Despite Strong Q4 Earnings?
Analyst Blog
by Nilanjan Banerjee
SLB reports strong Q4 earnings, but with clients becoming cautious in their discretionary spending, demand for its products & services is likely to be hurt.
SLB HAL BKR
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
Analyst Blog
by Zacks Equity Research
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
GSK NVS INCY
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
Analyst Blog
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
AZN CTMX CSTL ERAS
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
Analyst Blog
by Ekta Bagri
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
GSK MRK GILD
5 Stocks to Buy as Retail Sector Stages Roaring Recovery
Analyst Blog
by Ritujay Ghosh
Stocks like AMZN, WMT, URBN, COST and DECK are likely to benefit from the jump in retail sales.
AMZN WMT DECK COST URBN
Travelers to Report Q4 Earnings: Is a Beat in the Cards?
Analyst Blog
by Zacks Equity Research
Better performances across all three segments are likely to aid TRV's fourth-quarter results.
TRV WRB RNR SIGI
GigaCloud Stock Declines 24% in 3 Months: A Buying Opportunity?
Analyst Blog
by Shuvra Shankar Dey
Here, we present some insights into GCT's recent performance, market trends, and potential trajectory and discuss whether the stock is worth investing in.
RVLV GCT BYON
3 Reasons Why Growth Investors Shouldn't Overlook Merit Medical (MMSI)
Tale of the Tape
by Zacks Equity Research
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes.
MMSI
Fair Isaac Jumps 47% in a Year: How Should You Play the Stock?
Analyst Blog
by Zacks Equity Research
FICO drives innovation with strong platform growth, but competitive pressures could challenge client acquisition and retention.
IBM ADBE EXPGY FICO
Citigroup Posts Q4 Results: How Should You Approach the Stock Now?
Analyst Blog
by Riya Anand
C's business-restructuring efforts, along with the Fed rate cuts, look encouraging. Let us delve into other factors to analyze how to approach the C stock.
BAC WFC C
Knight-Swift to Report Q4 Earnings: What's in Store for the Stock?
Analyst Blog
by Zacks Equity Research
KNX's fourth-quarter 2024 performance is expected to have been weighed down by high costs related to driver wages, equipment, maintenance, fuel, and other expenses.
LUV CHRW KNX
Here's Why OUTFRONT Media Stock is an Apt Portfolio Pick Now
Analyst Blog
by Zacks Equity Research
OUT's diversified portfolio of advertising sites, digital billboard conversions and strategic expansions augur well for long-term growth.
CUZ OUT WELL
RGTI Surges 679% in 3 Months: More Room to Grow or Time to Sell?
Analyst Blog
by Nilanshi Mukherjee
RGTI benefits from an expanding clientele and a strong foothold in the quantum computing space despite quantum market challenges.
AMZN MSFT RGTI QBTS
Will Healthy Revenue Growth Boost Ericsson's Q4 Earnings Results?
Analyst Blog
by Zacks Equity Research
ERIC is expected to record a top-line expansion year over year in the fourth quarter of 2024, driven by healthy demand across several sectors and portfolio strength.
ADP ERIC IDCC META
Higher Expenses, Weak Asset Quality to Hurt Comerica's Q4 Earnings
Analyst Blog
by Zacks Equity Research
CMA's fourth-quarter 2024 performance is likely to have been hurt by rising expenses and deteriorating asset quality.
CMA ZION HTH
Airbnb Falls 5% in a Year: Should You Buy, Sell or Hold the Stock?
Analyst Blog
by Zacks Equity Research
Airbnb faces rising competition, margin compression and regulatory challenges, which raise short-term concerns that could keep investors cautious.
EXPE MMYT BKNG ABNB
UUUU Falls 28% in a Year: Should You Buy, Hold or Sell the Stock?
Analyst Blog
by Madhurima Das
The decreases in Energy Fuels' stock price and uranium prices have left investors confused about whether to buy the dip or wait for better clarity. Let us analyze.
CCJ DNN UUUU LEU
Is Zumiez Stock a Buy, Hold or Sell Post Holiday Sales Results?
Analyst Blog
by Zacks Equity Research
Zumiez's expansion of private-label products, new brands and focus on cost efficiency position it for growth despite recent challenges.
ZUMZ ANF DECK GAP
Carpenter Technology Stock Hits 52-Week High: What's Aiding It?
Analyst Blog
by Zacks Equity Research
CRS gains from strong market demand, cost-cutting initiatives and efforts to preserve liquidity.
CRS FSM ICL MAG
Gap Trades at Low P/E Multiple: Is it the Right Time to Buy the Stock?
Analyst Blog
by Rajani Lohia
GAP's brand strength, digital innovation and growth initiatives make it a top pick in retail. Strong fundamentals and undervaluation offer great investment potential.
ANF DECK BOOT GAP
AmEx Up 69% in Past Year: More Growth on the Horizon?
Analyst Blog
by Zacks Equity Research
AXP remains well-poised for growth on strong revenue growth, acquisitions and partnerships as well as a solid cash balance.
AXP EGBN BHLB FMAO
Energy Turns From Laggard to Leader: 5 Stock Winners
Analyst Blog
by Sweta Killa
The energy sector is leading in the initial weeks of 2025 after lagging over the past two years.
CEG PAA LNG BRY KGEI
Powell Industries Surges 89.9% in 6 Months: Time to Buy the Stock?
Analyst Blog
by Avisekh Bhattacharjee
POWL's strong prospects, driven by strength across its end markets, robust bookings, diversification efforts and attractive valuation, make it an ideal pick for investors.
ESE SBGSY ENS POWL
PepsiCo's $1.2B Buyout of Siete to Strengthen Its Food Portfolio
Analyst Blog
by Zacks Equity Research
PEP completes the buyout of Siete for $1.2 billion. This acquisition looks to expand its food portfolio, including nutritious, simple foods and ingredients.
PEP FRPT MKC UNFI
Kinsale Stock Trades Below 50-Day SMA: What Should Investors Know?
Analyst Blog
by Tanuka De
KNSL is set to gain from focus on the excess and supply market, prudent underwriting, lower expense ratio, solid investment portfolio and capital deployment.
KNSL RYAN CRBG EG
HCA Healthcare Pre-Q4 Earnings: Golden Opportunity or Fool's Gold?
Analyst Blog
by Zacks Equity Research
HCA's fourth-quarter results are expected to benefit from rising admissions and patient days. However, increasing expenses are a concern.
UHS HCA ACHC
3 Outsourcing Stocks to Consider Despite Industry Headwinds
Industry Outlook
by Arghyadeep Bose
The Zacks Outsourcing industry is well-positioned to gain from rising demand for business process outsourcing and AI and ML. PAYX, G, and BBSI are three stocks that are prime candidates to ride the demand wave.
PAYX G BBSI
Best Momentum Stocks to Buy for January 20th
Zacks #1 Rank Additions
by Zacks Equity Research
ARGX, ALLT and NGD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 20, 2025.
NGD ALLT ARGX
Company News for Jan 20, 2025
Corporate Summary
by Zacks Equity Research
Companies In The Article Are: INTC, NVO, VST, JBHT
INTC NVO JBHT VST
What Do Early Q4 Earnings Results Show?
Earnings Preview
by Sheraz Mian
The banks and other Finance companies gave us a strong start to the Q4 earnings season. However, we will see if this favorable trend continues as the Q4 reporting cycle really ramps up in the coming days.
DFS COF AXP ALLY